The Global Cannabis Intelligence Summit presentation, which was released to the market in early June, mentioned that AVE had topical cannabinoid formulations under development and provided some early supporting data.
No indication has been announced. There is some evidence from other studies (mainly preclinical) suggesting a potential for cannabinoids in the treatment of a range of skin conditions. These include acne vulgaris, allergic contact dermatitis, asteatotic dermatitis, atopic dermatitis, hidradenitis suppurativa, Kaposi sarcoma, pruritus, psoriasis, skin cancer and the cutaneous manifestations of systemic sclerosis.*
Some ASX-listed biotechs are already developing topical cannabinoid products. For example, Botanix has a gel for acne, solutions for rosacea and atopic dermatitis and antimicrobial and psoriasis ointments in clinical development (using a licensed non-chemical delivery system based on “kinetic energy”, called Permetrex) and Zelira has established a dermatology subsidiary with skincare products.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)